Tag: axess
First-in-human aXess graft trial shows high patency and low reintervention rates
“Absolutely novel and exciting”—that is how Frans Moll (University Medical Center Utrecht, Utrecht, The Netherlands) has described the aXess haemodialysis vascular graft as he...
Xeltis presents six-month first-in-human data on aXess graft
Xeltis has presented “highly-encouraging” six-month data from its first-in-human (FIH) aXess vascular graft trial at the 13th Congress of the Vascular Access Society (VAS;...
The aXess vascular graft: Potentially fulfilling a major unmet clinical need...
This advertorial is sponsored by Xeltis.
An de Vriese (Bruges, Belgium), who is playing a leading role in an ongoing European trial investigating the aXess...
Xeltis starts pivotal clinical trial of “first-ever” restorative synthetic haemodialysis access...
Xeltis announced today the initiation of a pivotal trial with the “first-ever” restorative synthetic haemodialysis access grafts, dubbed ‘Axess’.
The first two patients have been...
Xeltis presents “promising” first-in-human data on restorative haemodialysis access graft
Xeltis today announced what it describes as “very promising” preliminary efficacy and safety results from one of the centres participating in the AXESS study—a...
Restorative Axess graft demonstrates promising patency and safety in first-in-human study
The preliminary results from a clinical trial assessing a restorative haemodialysis access graft have shown promising early puncturing, patency and safety data. These findings...
Xeltis announces “promising outcomes” in restorative graft trials following EU financing
Xeltis has announced promising initial outcomes from two key vascular trials involving its restorative graft technologies.
According to the company, more than 350 successful dialysis...
Xeltis initiates European first-in-human trial of restorative haemodialysis access graft
Xeltis has announced initiation of a clinical trial evaluating Axess, which it claims is the first ever restorative synthetic haemodialysis access graft. Several patients...